Ivosidenib treatment in IDH-mutant WHO grade 4 astrocytomas: illustrative case

20260 citationsJournal Articlegreen Open Access

Authors

Brittany Owusu- Adjei · UMass Memorial Health Care

Janelle P. Renterghem · University of Massachusetts Chan Medical School

Cristina Hayes Meizoso · University of Massachusetts Chan Medical School

Rrita Daci · UMass Memorial Health Care

Constance J. Mietus · UMass Memorial Health Care

Peter S. Amenta · UMass Memorial Health Care

Mark D. Johnson

Abstract

Here the authors report the effects of the off-label use of ivosidenib. The INDIGO trial published evidence of efficacy in using an IDH inhibitor for low-grade gliomas. The role of these drugs in high-grade IDH-mutant gliomas is currently unknown. Further studies are needed to assess their impact on overall and progression-free survival. https://thejns.org/doi/10.3171/CASE25572.

Topics & Keywords

Glioma Diagnosis and Treatment Hedgehog Signaling Pathway Studies Neuroblastoma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Neurosurgery Case Lessons

Volume 11, Issue 7

DOI: 10.3171/case25572

Field-Weighted Citation Impact: 0.00